The impact of genome wide supported microRNA-137 (MIR137) risk variants on frontal and striatal white matter integrity, neurocognitive functioning, and negative symptoms in schizophrenia

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 168, Issue 5, 2015, Pages 317-326

  Kuswanto, Carissa Nadia ^a   Sum, Min Yi ^a   Qiu, Anqi ^b   Sitoh, Yih Yian ^c   Liu, Jianjun ^d   Sim, Kang ^a  

^a INSTITUTE OF MENTAL HEALTH   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^d GENOME INSTITUTE OF SINGAPORE   (Singapore)

Author keywords

Diffusion tensor imaging; MicroRNA; Negative symptoms; Neurocognitive deficits; Schizophrenia

Indexed keywords

ADENINE; GUANINE; MICRORNA; MICRORNA 137; UNCLASSIFIED DRUG; MIRN137 MICRORNA, HUMAN;

ADULT; ALLELE; ARTICLE; ATTENTION; COGNITION; CONTROLLED STUDY; CORPUS STRIATUM; DIFFUSION TENSOR IMAGING; DSM-IV; FEMALE; FRACTIONAL ANISOTROPY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROBIOLOGY; NUCLEAR MAGNETIC RESONANCE SCANNER; ORBITAL CORTEX; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; WHITE MATTER; ASIAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; PSYCHOSIS; RISK; YOUNG ADULT;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; COGNITION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PSYCHOTIC DISORDERS; RISK; SCHIZOPHRENIA; WHITE MATTER; YOUNG ADULT;

EID: 84930927803     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.32314     Document Type: Article

References (48)

1. Barrett JC, Fry B, Maller J, Daly MJ. 2005. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 21(2):263-265.
2. Bernacer J, Corlett PR, Ramachandra P, McFarlane B, Turner DC, Clark L, Robbins TW, Fletcher PC, Murray GK. 2013. Methamphetamine-induced disruption of frontostriatal reward learning signals: Relation to psychotic symptoms. Am J Psychiatry 170(11):1326-1334.
3. Chudasama Y, Robbins TW. 2006. Functions of frontostriatal systems in cognition: Comparative neuropsychopharmacological studies in rats, monkeys, and humans. Biol Psychol 73(1):19-38.
4. Cousijn H, Eissing M, Fernández G, Fisher SE, Franke B, Zwiers M, Harrison PJ, Arias-Vásquez A. 2014. No effect of schizophrenia risk genes MIR137, TCF4, and ZNF804A on macroscopic brain structure. Schizophr Res DOI: 10.1016/j.schres.2014.08.007
5. Cox SR, Bastin ME, Ferguson KJ, Maniega SM, Macpherson SE, Deary IJ, Wardlaw JM, MacLullich AMJ. 2014. Brain white matter integrity and cortisol in older men: The Lothian Birth Cohort 1936. Neurobiol Aging DOI: 10.1016/j.neurobiolaging.2014.06.022
6. Cummings E, Donohoe G, Hargreaves A, Moore S, Fahey C, Dinan TG, McDonald C, O'Callaghan E, O'Neill FA, Waddington JL, Murphy KC, Morris DW, Gill M, Corvin A. 2013. Mood congruent psychotic symptoms and specific cognitive deficits in carriers of the novel schizophrenia risk variant at MIR-137. Neurosci Lett 532:33-38.
7. Diwadkar VA, Bakshi N, Gupta G, Pruitt P, White R, Eickhoff SB. 2014. Dysfunction and disconnection in cortical-striatal networks during sustained attention: genetic risk for schizophrenia or bipolar disorder and its impact on brain network function. Front Psychiatry 5:1-13.
8. First MB, Spitzer RL, Gibbon M, Williams JBW. 1994. Structured clinical interview for DSM-IV axis I disorders-patient version. (SCID-P). Washington, DC: American Psychiatric Press.
9. First MB, Spitzer RL, Gibbon M, Williams JBW. 2002. Structured clinical interview for DSM-IV axis I disorders-non-patient version. (SCID-NP). Washington, DC: American Psychiatric Press.
10. Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, van der Kouwe A, Killiany R, Kennedy D, Klaveness S, Montillo A, Makris N, Rosen B, Dale AM. 2002. Whole brain segmentation: Automated labeling of neuroanatomical structures in the human brain. Neuron 33(3):341-355.
11. Fischl B, van der Kouwe A, Destrieux C, Halgren E, Segonne F, Salat DH, Busa E, Seidman LJ, Goldstein J, Kennedy D, Caviness V, Makris N, Rosen B, Dale AM. 2004. Automatically parcellating the human cerebral cortex. Cereb Cortex 14(1):11-22.
12. Fornito A, Harrison BJ, Goodby E, Dean A, Ooi C, Nathan PJ, Lennox BR, Jones PB, Suckling J, Bullmore ET. 2013. Functional dysconnectivity of corticostriatal circuitry as a risk phenotype for psychosis. JAMA Psychiatry 70(11):1143-1151.
13. Green MJ, Cairns MJ, Wu J, Dragovic M, Jablensky A, Tooney PA, Scott RJ, Carr VJ. Australian Schizophrenia Research Bank. 2013. Genome-wide supported variant MIR137 and severe negative symptoms predict membership of an impaired cognitive subtype of schizophrenia. Mol Psychiatry 18(7):774-780.
14. Guan F, Zhang B, Yan T, Li L, Liu F, Li T, Feng Z, Zhang B, Liu X, Li S. 2014. MIR137 gene and target gene CACNA1C of miR-137 contribute to schizophrenia susceptibility in Han Chinese. Schizophr Rese 152(1):97-104.
15. Guella I, Sequeira A, Rollins B, Morgna L, Torri F, van Erp TG, Myers RM, Barchas JD, Schatzberg AF, Watson SJ, Akil H, Bunney WE, Potkin SG, Macciardi F, Vawter MP. 2013. Analysis of miR-137 expression and rs1625579 in dorsolateral prefrontal cortex. J Psychiatr Res 47(9):1215-1221.
16. Hill MJ, Donocik JG, Nuamah RA, Mein CA, Sainz-Fuertes R, Bray NJ. 2014. Transcriptional consequences of schizophrenia candidate miR-137 manipulation in human neural progenitor cells. Schizophr Res 153(1-3):225-230.
17. Howes OD, Fusar-Poli P, Bloomfield M, Selvaraj S, McGuire P. 2012. From the prodome to chronic schizophrenia: The neurobiology underlying psychotic symptoms and cognitive impairments. Curr Pharm Des 18(4):459-465.
18. Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261-276.
19. Keefe RSE, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. 2004. The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 68(2-3):283-297.
20. Kelly S, Morris DW, Mothersill O, Rose EJ, Fahey C, O'Brien C, O'Hanlon E, Gill M, Corvin AP, Donohoe G. 2014. Genome-wide schizophrenia variant at MIR137 does not impact white matter microstructure in healthy participants. Neurosci Lett 574:6-10.
21. Kim AH, Parker EK, Williamson V, McMichael GO, Fanous AH, Vladimirov VI. 2012. Experimental validation of candidate schizophrenia gene ZNF804A as target for hsa-miR-137. Schizophr Res 141(1):60-64.
22. Kwon E, Wang W, Tsai LH. 2013. Validation of schizophrenia-associated genes CSMD1, C10orf26, CACNA1C and TCF4 as miR-137 targets. Mol Psychiatry 18(1):11-12.
23. Lett TA, Chakavarty MM, Felsky D, Brandl EJ, Tiwari AK, Gonçlaves VF, Rajji TK, Daskalakis ZJ, Meltzer HY, Lieberman JA, Lerch JP, Mulsant BH, Kennedy JL, Voineskos AN. 2013. The genome-wide supported microRNA-137 variant predicts phenotypic heterogeneity within schizophrenia. Mol Psychiatry 18(4):443-450.
24. Li M, Su B. 2013. Impact of the genome-wide schizophrenia risk single nucleotide polymorphism (rs1625579) in miR-137 on brain structures in healthy subjects. Psychiatr Genet 23(6):267.
25. Liu B, Zhang X, Hou B, Li J, Qiu C, Qin W, Yu C, Jiang T. 2014. The impact of MIR137 on dorsolateral prefrontal-hippocampal functional connectivity in healthy subjects. Neuropsychopharmacology 39(9):1-8.
26. Millan MJ, Fone K, Steckler T, Horan WP. 2014. Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol 24(5):645-692.
27. Mizoguchi K, Yuzurihara M, Ishige A, Sasaki H, Chui DH, Tabira T. 2000. Chronic stress induces impairment of spatial working memory because of prefrontal dopaminergic dysfunction. J Neurosci 20(4):1568-1574.
28. Mizoguchi K, Yuzurihara M, Nagata M, Ishige A, Sasaki H, Tabira T. 2002. Dopamine-receptor stimulation in the prefrontal cortex ameliorates stress-induced rotarod impairment. Pharmacol Biochem Behav 72(3):723-728.
29. Mizoguchi K, Ishige A, Takeda S, Aburada M, Tabira T. 2004. Endogenous glucocorticoids are essential for maintaining prefrontal cortical cognitive function. J Neurosci 24(24):5492-5499.
30. Mothersill O, Morris DW, Kelly S, Rose EJ, Fahey C, O'Brien C, Lyne R, Reilly R, Gill M, Corvin AP, Donohoe G. 2014. Effects of MIR137 on fronto-amygdala functional connectivity. Neuroimage 90:189-195.
31. Nieoullon A. 2002. Dopamine and the regulation of cognition and attention. Prog Neurobiol 67(1):53-83.
32. Ripke S, O'Dushlaine C, Chambert K, Moran JL, Kähler AK, Akterin S, Bergen SE, Collins AL, Crowley JJ, Fromer M, et al. 2013. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet 45(10):1150-1161.
33. Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Holmans PA, Lin DY, Duan J, Ophoff RA, Andreassen OA, et al. 2011. Genome-wide association study identifies five new schizophrenia loci. Nat Genet 43(10):969-978.
34. Rose EJ, Morris DW, Fahey C, Cannon D, McDonald C, Scanlon C, Kelly S, Gill M, Corvin A, Donohoe G. 2014. The miR-137 schizophrenia susceptibility variant rs1625579 does not predict variability in brain volume in a sample of schizophrenic patients and healthy individuals. Am J Med Genet B 165B(6):467-471.
35. Meza-Sosa KF, Pedraza-Alva G, Pérez-Martínez L. 2014. MicroRNAs: Key triggers of neuronal cell fate. Front Cell Neurosci 8(175):1-13.
36. Nieoullon A. 2002. Dopamine and the regulation of cognition and attention. Prog Neurobiol 67(1):53-83.
37. Schizophrenia Working Group of the Psychiatric Genomics Consortium. 2014. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511(7510):421-427.
38. Smrt RD, Szulwach K, Pfeiffer RB, Li X, Guo W, Pathania M. 2010. MicroRNA miR-137 regulates neuronal maturation by targeting ubiquiting ligase Mind Bomb-1. Stem Cells 28(6):1060-1070.
39. Strazisar M, Cammaerts S, van der Ven K, Forero DA, Lenaerts AS, Nordin A, Almeida-Souza L, Genovese G, Timmerman V, Liekens A, De Rijk P, Adolfsson R, Callaerts P, Del-Favero J. 2014. MIR137 variants identified in psychiatric patients affect synaptogenesis and neuronal transmission gene sets. Mol Psychiatry Jun 3, DOI: 10.1038/mp.2014.53
40. Szulwach KE, Li X, Smrt RD, Li Y, Luo Y, Lin L, Santistevan NJ, Li W, Zhao X, Jin P. 2010. Cross talk between microRNA and epigenetic regulation in adult neurogenesis. J Cell Biol 189(1):127-141.
41. Vallès A, Martens GJ, De Weerd P, Poelmans G, Aschrafi A. 2014. MicroRNA-137 regulates a glucocorticoid receptor-dependent signalling network: implications for the etiology of schizophrenia. J Psychiatry Neurosci 39(5):312-320.
42. Van Craenenbroeck K, De Bosscher K, Berghe WV, Vanhoenacker P, Haegeman G. 2005. Role of glucocorticoids in dopamine-related neuropsychiatric disorders. Mol Cell Endocrinol 245(102):10-22.
43. Van Erp TGM, Guella I, Vawter MP, Turner J, Brown GG, McCarthy G, Greve DN, Glover GH, Calhoun VD, Lim KO, Bustillo JR, Belger A, Ford JM, Mathalon DH, Diaz M, Preda A, Nguyen D, Macciardi F, Potkin SG. 2014. Schizophrenia miR-137 locus risk genotype is associated with dorsolateral prefrontal cortex hyperactivation. Biol Psychiatry 75(5):398-405.
44. Vink M, Zandbelt BB, Gladwin T, Hillegers M, Hoogendam JM, van den Wildenberg WPM, Plessis SD, Kahn RS. 2014. Frontostriatal activity and connectivity increase during proactive inhibition across adolescence and early adulthood. Hum Brain Mapp 35(9):4415-4427.
45. Whalley HC, Papmeyer M, Romaniuk L, Sprooten E, Johnstone EC, Hall J, Lawrie SM, Evans KL, Blumberg HP, Sussmann JE, McIntosh AM. 2012. Impact of a microRNA MIR137 susceptibility variant on brain function in people at high genetic risk of schizophrenia or bipolar disorder. Neuropsychopharmacology 37(12):2720-2729.
46. Willemsen MH, Vallès A, Kirkels LAMH, Mastebroek M, Loohuis NO, Kos A, Wissink-Lindhout WM, de Brouwer AP, Nillesen WM, Pfundt R, Holder-Espinasse M, Vallée L, Andrieux J, Coppens-Hofman MC, Rensen H, Hamel BC, van Bokhoven H, Aschrafi A, Kleefstra T. 2011. Chromosome 1p21.3 microdeletions comprising DPYD and MIR137 are associated with intellectual disability. J Med Genet 48(12):810-818.
47. Wright C, Turner JA, Calhoun VD, Perrone-Bizzozero N. 2013. Potential impact of miR-137 and its targets in schizophrenia. Front Genet 4(58):1-14.
48. Yin J, Lin J, Luo X, Chen Y, Li Z, Ma G, Li K. 2014. MiR-137: A new player in schizophrenia. Int J Mol Sci 15(2):3262-3271.